AU2003287188A1 - Activation of hcv-specific cells - Google Patents

Activation of hcv-specific cells

Info

Publication number
AU2003287188A1
AU2003287188A1 AU2003287188A AU2003287188A AU2003287188A1 AU 2003287188 A1 AU2003287188 A1 AU 2003287188A1 AU 2003287188 A AU2003287188 A AU 2003287188A AU 2003287188 A AU2003287188 A AU 2003287188A AU 2003287188 A1 AU2003287188 A1 AU 2003287188A1
Authority
AU
Australia
Prior art keywords
hcv
activation
specific cells
cells
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003287188A
Other versions
AU2003287188A8 (en
Inventor
Steve Coates
Michael Houghton
Xavier Paliard
Mark Selby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2003287188A1 publication Critical patent/AU2003287188A1/en
Publication of AU2003287188A8 publication Critical patent/AU2003287188A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003287188A 2002-10-25 2003-10-24 Activation of hcv-specific cells Abandoned AU2003287188A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28134102A 2002-10-25 2002-10-25
US10/281,341 2002-10-25
PCT/US2003/033610 WO2004039950A2 (en) 2002-10-25 2003-10-24 Activation of hcv-specific cells

Publications (2)

Publication Number Publication Date
AU2003287188A1 true AU2003287188A1 (en) 2004-05-25
AU2003287188A8 AU2003287188A8 (en) 2004-05-25

Family

ID=32228760

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003287188A Abandoned AU2003287188A1 (en) 2002-10-25 2003-10-24 Activation of hcv-specific cells

Country Status (4)

Country Link
EP (1) EP1576125A4 (en)
AU (1) AU2003287188A1 (en)
CA (1) CA2505611A1 (en)
WO (1) WO2004039950A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776343B1 (en) 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
CN1809584B (en) * 2003-04-25 2010-12-01 诺华疫苗和诊断公司 Compositions comprising cationic microparticles and HCV E1E2 DNA and methods of use thereof
WO2005113837A2 (en) * 2004-05-17 2005-12-01 Chiron Corporation Truncated hepatitis c virus ns5 domain and fusion proteins comprising same
KR100958505B1 (en) * 2004-07-18 2010-05-17 씨에스엘 리미티드 Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
JP5474547B2 (en) 2006-08-25 2014-04-16 ノバルティス アーゲー HCV fusion polypeptide
WO2011163558A1 (en) * 2010-06-25 2011-12-29 Abbott Laboratories Materials and methods for assay of anti-hepatitis c virus (hcv) antibodies
CN103819565B (en) * 2014-02-26 2016-11-09 广州万孚生物技术股份有限公司 HCV restructuring fused antigen and expressing gene and preparation method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US6312889B1 (en) * 1990-04-04 2001-11-06 Chiron Corporation Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US6153378A (en) * 1992-10-16 2000-11-28 Bionova Corporation Diagnosis of, and vaccination against, a positive stranded RNA virus using an isolated, unprocessed polypeptide encoded by a substantially complete genome of such virus
JP3945822B2 (en) * 1996-05-24 2007-07-18 カイロン コーポレイション Multiple epitope fusion protein
EP1539809A4 (en) * 2002-07-02 2006-03-08 Chiron Corp Hcv fusion proteins with modified ns3 domains

Also Published As

Publication number Publication date
CA2505611A1 (en) 2004-05-13
WO2004039950A2 (en) 2004-05-13
EP1576125A2 (en) 2005-09-21
AU2003287188A8 (en) 2004-05-25
WO2004039950A3 (en) 2007-11-22
EP1576125A4 (en) 2008-09-03

Similar Documents

Publication Publication Date Title
AU2003265826A1 (en) Electrolyte
AU2003239909A1 (en) Enhanced-service provision
AU1236801A (en) Activation of hcv-specific t cells
AU2003255831A1 (en) Delayed-gelation solution
AU2003238930A1 (en) Enzymes
AU2003236991A1 (en) Representations of processes
AU2003290432A1 (en) T cell activating gene
AU2003211585A1 (en) Reaction cell and method of using the cell
AU2003242258A1 (en) Battery
AU2003232986A1 (en) Dc-dc-converter
AU2003269339A1 (en) Very large vessel construction
AU2003253918A1 (en) Methods of modifying behavior of cd9-expressing cells
AU2003228139A1 (en) Bioreactor
AU2003287188A1 (en) Activation of hcv-specific cells
AU2003268284A1 (en) Self-dampening vessel
AU2002316552A1 (en) Inhibitor of t cell activation
AU2003295790A1 (en) Modulation of iap-like expression
AU2002255259A1 (en) Electroacoustic converter
AU2003245747A1 (en) Enzymes
AU2003235285A1 (en) Battery
AU2003216376A1 (en) Enzymes
AU2003300111A1 (en) Sperm-induced cellular activation
AU2003254611A1 (en) Scalpel
AU2003217743A1 (en) Magnetic immobilization of cells
AU2003208778A1 (en) Membrane reactor

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase